
FDA Approves At-Home Subcutaneous Injection for Early Alzheimer’s
The U.S. Food and Drug Administration has cleared Leqembi Iqlik for the initiation of Alzheimer's treatment, marking a shift toward at-home care. The subcutaneous autoinjector allows patients to begin therapy outside clinical settings, providing a weekly alternative to traditional intravenous infusions for those in early stages of the disease.























